home / stock / spro / spro news


SPRO News and Press, Spero Therapeutics Inc.

Stock Information

Company Name: Spero Therapeutics Inc.
Stock Symbol: SPRO
Market: NASDAQ
Website: sperotherapeutics.com

Menu

SPRO SPRO Quote SPRO Short SPRO News SPRO Articles SPRO Message Board
Get SPRO Alerts

News, Short Squeeze, Breakout and More Instantly...

SPRO - Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy

2026-02-11 08:43:11 ET ... Read the full article on Seeking Alpha For further details see: Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy

SPRO - Top 5 Small-cap Biotech Stocks of 2025

2025-12-30 14:10:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks. After dropping to a low of 3,637.05 in October 2023, the ...

SPRO - Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its dev...

SPRO - Spero Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $5.44M

2025-11-13 16:13:50 ET More on Spero Therapeutics Spero Therapeutics, Inc. (SPRO) Presents at IDWeek 2025 - Slideshow Seeking Alpha’s Quant Rating on Spero Therapeutics Historical earnings data for Spero Therapeutics Financial information for Spero The...

SPRO - Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025 Spero’s development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administr...

SPRO - Here are the major earnings after the close Thursday

2025-11-13 10:00:00 ET Read the full article on Seeking Alpha For further details see: Here are the major earnings after the close Thursday

SPRO - Expected US Company Earnings on Thursday, November 13th, 2025

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

SPRO - Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it w...

SPRO - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be shared with regulatory authorities to support regulatory filings CAMBRI...

SPRO - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announces presentat...

Next 10